


Pharmacy BULLETIN BOARD

Industry Issue ■ Monday July 21, 2014



Now Listed on Alberta and Saskatchewan Formularies!!!

P^rTaro-Carbamazepine
Carbamazepine Tablets 200mg


Taro Pharmaceuticals is pleased to announce that Taro-Carbamazepine Tablets 200mg is now an Interchangeable Benefit on Alberta and Saskatchewan Formularies.

- Bioequivalent to Tegretol^{®1}
- High Quality, Lower Price Alternative

Form	Strength	DIN	Size	UPC	Wholesaler			
					Mckesson	K&F	Procurity	McMahon
Tablet	200 mg	02407515	500	063691072671	063139	147883	T.B.A.	10071281

For more information, or to place an order for Taro-Carbamazepine 200 mg Tablets, please contact your Taro Representative, your wholesaler, our Customer Service department at **1-800-268-1975**, or visit our Website at www.taro.ca.

¹ Data on file, Taro Pharmaceuticals Inc.
[®]Tegretol is a registered trademark of Novartis Pharmaceuticals Canada Inc.
 TARO is a registered trademark of Taro Pharmaceuticals Inc.



Available for Immediate Shipping!!!

P^rTaro-Docusate
Docusate Sodium Capsules 100mg

Taro Pharmaceuticals is pleased to announce that Taro-Docusate 100mg is available for immediate shipping.

- Listed in most Provincial Formularies
- Same Size, Shape and Colour as Soflax^{®2}
- Stool Softener

Capsules 100 mg

DIN	Size	UPC	Wholesaler			
			Mckesson	K&F	Procurity	McMahon
00716731	100	063691069930	012028	120028	269956	26612401
	1000	063691069947	012029	120029	270350	26586301

For more information, or to place an order for Taro-Docusate, please contact your Taro Representative, your wholesaler, our Customer Service department at **1-800-268-1975** or visit our Website at www.taro.ca.

¹ Data on file, Taro Pharmaceuticals Inc.
[®]Soflax is a registered trademark of Pharmascience Inc.
 TARO is a registered trademark of Taro Pharmaceuticals Inc.

UriSec[®] emollient creams and lotions are patient friendly formulations ideal for winter dryness and itchy skin.

Product	Sizes	Odan Code	Kohl & Frisch Code	McKesson Code	McMahon Code
UriSec [®] 10% Cream NPN 80005397	75 g	38075	32617	513085	26638401
	120 g	38045	32618	513341	26638301
UriSec [®] 12% Lotion NPN 00514896	250 mL	230J	48909	115493	26623101
UriSec [®] 22% Cream NPN 00396125	120 g	220Q	46312	115444	26623201
	225 g	220C	-	153486	26537801
	454 g	220R	46309	848549	26632301
UriSec [®] 40 Cream NPN 80005531	15 g	45014	114939	003743	-
	30 g	45028	32606	799437	27127401
	100 g	45067	32616	799494	26640001

UriSec[®] products are prescribed by Dermatologists and Physicians and are used by both patients and hospitals across Canada.

To order, please contact your wholesaler or Odan at 1-800-387-9342 or by e-mail at info@odanlab.com. You can also visit our website at www.odanlab.com



UriSec[®] is a registered trademark of Odan Laboratories Ltd.

FROM THE NEWSWIRE

OTTAWA: The Honourable Rona Ambrose, Minister of Health, announced funding for three recipients of the Partners for Engagement and Knowledge Exchange (PEKEs) grants through the Canadian Institutes of Health Research's (CIHR) Pathways to Health Equity for Aboriginal Peoples (or Pathways) signature initiative. The overall goal of Pathways is to promote health equity among First Nations, Métis and Inuit peoples in four key areas: suicide prevention, obesity and diabetes, tuberculosis, and oral health.

MONTREAL: Judes Poirier, PhD, C.Q., from the Douglas Mental Health Institute and McGill University in Montréal (Canada) and his team have discovered that a relatively frequent genetic variant actually conveys significant protection against the common form of Alzheimer's disease and can delay the onset of the disease by as much as 4 years. This discovery opens new avenues for treatment against this devastating disease.

OTTAWA: Health Canada is advising patients and healthcare professionals of new safety information regarding testosterone hormone replacement products and a risk of serious and possibly life-threatening cardiovascular (heart and blood vessel) problems.



Lower Cost Generic Alternative to Pennsaid®¹!!!

P^rTaro-Diclofenac

Diclofenac Sodium Topical Solution 1.5%

Taro Pharmaceuticals is pleased to announce the recent launch of Taro-Diclofenac Topical Solution 1.5% which is Available for Immediate Shipping.

- Bioequivalent to Pennsaid®¹
- High Quality, Lower Price Alternative
- Topical Anti-inflammatory; Analgesic²
- New Convenient 150 mL Size

Topical Solution 1.5%

DIN	Size	UPC	Wholesaler			
			Mckesson	K&F	Procurity	McMahon
02420988	2 x 60 mL	063691073517	060770	147411	256323	10071421
	150 mL	063691073548	060771	147409	256480	10071400

For more information, or to place an order for Taro-Diclofenac topical solution 1.5%, please contact your Taro Representative, your wholesaler, our Customer Service department at **1-800-268-1975** or visit our Website at www.taro.ca.

¹ Data on file, Taro Pharmaceuticals Inc.
² P^rTaro-Diclofenac Product Monograph.
 ® Pennsaid is a registered trademark of Nuvo Research Inc.
 TARO is a registered trademark of Taro Pharmaceuticals Inc.



Now listed on the List of Medications in Quebec!!!

P^rTaro-Zoledronic Acid Concentrate

Zoledronic Acid Injection 4 mg/5 mL*

Must be diluted before use - for I.V. Infusion

Taro Pharmaceuticals is pleased to announce the coverage of Taro-Zoledronic Acid Concentrate 4mg/5mL in Quebec.

- Generic Version of Zometa®¹
- High Quality Product, Lower Price Alternative

Form	Strength	DIN	Size	UPC	Wholesaler	
					Mckesson	K&F
Vial (Concentrate, must be diluted before use, for I.V. Infusion)	4mg/5mL	02415186	1 Vial (5mL)	063691073401	058569	146974

For more information, or to place an order for Taro-Zoledronic Acid Concentrate, please contact your Taro Representative, your wholesaler, our Customer Service department at **1-800-268-1975** or visit our Website at www.taro.ca.

¹ Data on file, Taro Pharmaceuticals Inc.
 ®Zometa is a registered trademark of Novartis Pharmaceuticals Canada Inc.
 *Incorporated as the monohydrate
 Taro is a registered trademark of Taro Pharmaceuticals Inc.

To include your communication in the next issue, please contact: Health Response

T: 416-863-5403 | F: 416-863-9620 | hrc@healthresponse.ca

Next Issue: Monday August 11th, 2014

Deadline: Thursday August 7th, 2014